Article Type

Original Study


Background Diabetes mellitus (DM) is a worldwide metabolic disorder that is associated with many complications. Recently, it has been noted that estrogen has a beneficial effect on type II DM. Objective The aim of this study was to prove that the use estrogen could improve the metabolic state in type II DM. Materials and methods Eighty adult female albino rats weighing 200–250 g were used. Diabetes was induced by means of a single intraperitoneal injection of streptozotocin 40 mg/kg. Rats were divided into the following groups: the control group (group C); the ovariectomized control group (group OVX C); the diabetic group (group D); the diabetic ovariectomized group (group OVX D); the diabetic insulin-treated group (group DI), in which insulin was administered at a dose of 10–20 IU/kg for 6 days/week by means of subcutaneous injection; the diabetic ovariectomized insulin-treated group (group OVX DI); the diabetic nonovariectomized estrogen and insulin treated group (group DEI), in which estradiol was administered at a dose of 50 μg/kg; and the diabetic ovariectomized estrogen and insulin treated group (group OVX DEI). After 12 weeks, fasting blood glucose level, glycosylated hemoglobin level, and fasting serum lipids were measured. Retroperitoneal adipose tissue was taken for measurement of insulin receptor substrate 1 (IRS1) gene expression using reverse transcriptase-PCR. Results Combined estrogen and insulin treatment induced a significant decrease in fasting blood glucose, HbA1C Glycated hemoglobin, and fasting serum lipid profile with an increase in IRS1 protein gene expression level. Conclusion Results should be considered in prediabetic and or diabetic postmenopausal women.